Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2026.1786154 Correction Correction: TAFRO syndrome requiring combined IL 6 and IL 1 inhibition: a case report Frontiers Production Office * Writing – original draft Correspondence: Frontiers Production Office, production.office@frontiersin.org 23 01 2026 2026 17 1786154 12 01 2026 12 01 2026 Copyright © 2026 Frontiers Production Office. 2026 Frontiers Production Office https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on TAFRO syndrome requiring combined IL 6 and IL 1 inhibition: a case report By Sultan AW, Grießhammer E, Hinrichs C, Trenkmann L, Oschlies I, Hanitsch LG, Haibel H, Schneider T and Leistner R (2026) Front. Immunol. 16:1729525. doi: 10.3389/fimmu.2025.1729525 case report combined IL-6 and IL-1 inhibition idiopathic multicentric Castleman disease iMCD TAFRO syndrome section-at-acceptance Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

There was a mistake in Table 2 as published. An incorrect file was erroneously published in place of Table 2. The corrected Table 2 appears below.

Comparison of diagnostic results in idiopathic multicentric Castleman disease with TAFRO features (iMCD-TAFRO), hemophagocytic lymphohistiocytosis (HLH), and other relevant mimics (such as iMCD-NOS, autoimmune diseases, and lymphoma) (3, 7–9, 14, 17).

Feature iMCD-TAFRO HLH Other Mimics (iMCD-NOS, Autoimmune, Lymphoma)
Clinical Presentation Acute onset; fever; anasarca; abdominal pain; organomegaly (hepatosplenomegaly); may lack prominent lymphadenopathy Acute onset; fever; hepatosplenomegaly; cytopenias; neurologic symptoms; rash Subacute/chronic; variable fever; lymphadenopathy; organomegaly; less anasarca
Thrombocytopenia Marked, often transfusion-resistant Marked, part of bicytopenia Mild or absent; iMCD-NOS may have thrombocytosis
Anasarca/Edema Prominent, often with pleural effusions May occur, but less prominent Rare; may occur in severe autoimmune disease
Fever High, persistent High, persistent Variable; less common in indolent mimics
Organomegaly Hepatosplenomegaly, mild lymphadenopathy Hepatosplenomegaly, lymphadenopathy Lymphadenopathy prominent in lymphoma/iMCD-NOS
Renal Dysfunction Common, often with proteinuria May occur (secondary to multiorgan failure) Variable; less common
Hemophagocytosis Absent or rare Characteristic (bone marrow, other tissues) Absent
Hyperferritinemia Mild to moderate Marked, often >10,000 ng/mL Mild or absent
CRP/ESR Elevated CRP, variable ESR Elevated CRP, variable ESR Elevated in inflammation
IgG/Hypergamma-globulinemia Normal or low IgG; polyclonal gammopathy rare Normal or low IgG iMCD-NOS: polyclonal hypergammaglobulinemia
Anti-SSA/Ro Antibodies Often positive Negative Negative
Imaging Mild lymphadenopathy; marked effusions/anasarca; organomegaly Hepatosplenomegaly; lymphadenopathy; CNS lesions (MRI) Prominent lymphadenopathy (lymphoma); variable effusions
Bone Marrow Reticulin fibrosis; mild plasmacytosis Hemophagocytosis; cytopenias Plasmacytosis (iMCD-NOS); malignant cells (lymphoma)

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland